This site uses cookies to improve your browsing experience; the website may not work as expected without them. By continuing to browse this site, you consent to the use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy
Vamorolone Designated Promising Innovative Medicine (PIM) for Treatment of Duchenne Muscular Dystrophy by the UK MHRA
Rockville, MD, 21 October 2019
Santhera Pharmaceuticals announces that the UK’s Medicines and Healthcare Products Regulatory Agency has informed ReveraGen BioPharma about having designated vamorolone a Promising Innovative Medicine . . .
Vamorolone Designated Promising Innovative Medicine (PIM) for treatment in Duchenne muscular dystrophy
Rockville, MD, 17 October 2019
In the UK the Early Access to Medicines Scheme (EAMS) is a regulatory path by the MRHA that aims to give patients with life threatening or . . .
Top-line data of 18-month vamorolone treatment of Duchenne muscular dystrophy patients shows continued improvement of symptoms with reduction in corticosteroid safety concerns
Rockville, MD – 5 October 2019
A presentation at the 24th International Annual Congress of the World Muscle Society (WMS) in Copenhagen, Denmark reported top-line data from 18-month treatment of Duchenne muscular dystrophy (DMD) patients (VBP15-LTE trial).
Vamorolone Treatment of Duchenne Muscular Dystrophy Patients Leads to Improvements in Motor Function
Rockville, MD – 18 August 2019
A publication in the journal Neurology was released today describing efficacy studies of vamorolone, a treatment option being evaluated as a potentially safer alternative to corticosteroids, in boys with Duchenne muscular dystrophy.
Vamorolone (VBP15) First-in-patient Studies in Duchenne Muscular Dystrophy Published
Rockville, MD – 2 October 2018
A clinical trial of vamorolone in 48 boys with Duchenne muscular dystrophy entitled “Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug” has been
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystrophy
Rockville, MD – 22 August 2018
ReveraGen BioPharma, Inc. today announced the initiation and first patient enrollment in a double-blind, placebo- and prednisone-controlled clinical trial (VBP15-004) of vamorolone, a first-in-class dissociative steroidal anti-inflammatory, in Duchenne muscular dystrophy.
Vamorolone (VBP15) Top Line Data Shows Improvements in Strength and Endurance in Boys with Duchenne Muscular Dystrophy
Rockville, MD – 26 June 2018
Vamorolone (VBP15) Top Line Data Shows Improvements in Strength and Endurance in Boys with Duchenne Muscular Dystrophy.
Finalists Selected – 3rd Annual BioHealth Capital Region Crab Trap Competition
– Winner to be announced during 2018 BioHealth Capital Region Forum –
ROCKVILLE, MARYLAND, April 12, 2018 – Five companies have been selected to present to a panel of investor judges and an audience of industry leaders during the 2018 BioHealth
ReveraGen BioPharma Receives FDA Fast Track Designation for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
ROCKVILLE, Maryland, March 24, 2017
ReveraGen BioPharma Inc, a privately held corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for vamorolone (VBP15) for the treatment of patients with Duchenne muscular dystrophy. This designation
Actelion obtains an option vamorolone from ReveraGen
Vamorolone, a novel compound for the treatment of Duchenne Muscular Dystrophy, holds potential to better preserve muscle function and prolong ambulation for the patient, without some of the side effects associated with glucocorticoid therapy.
ALLSCHWIL, SWITZERLAND, and ROCKVILLE (MD), USA –